RGNX

Latest SEC Filings & News for RGNX

3 most recent filings and news items mentioning RGNX. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day
curl "https://api.brieftape.com/v1/tickers/RGNX/news?limit=20"

Pull RGNX filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day
RegulatoryAug 6, 2026Positive

RGX-202 BLA for DMD on track for Q3 submission, with rabies virus data Showing durable efficacy

REGENXBIO reported strong second-quarter results, announcing the initiation of RGX-202 BLA filing and up to ~2H 2027 catalyst expectations, extending its cash runway consistent with its gene therapy pipeline development progress.

View filing at SEC.gov →
MarketsJul 17, 2026Neutral

Crude Oil Surges 4%; Travelers Posts Upbeat Q2 results

Crude Oil Surges 4%; Travelers Posts Upbeat Q2 results

View filing at SEC.gov →
RegulatoryJun 29, 2026Positive

Regenerxbio dosed first patient in sura-vec trial for diabetic retinopathy.

Regenerxbio announced the first patient dosed in the NAAVIGATE trial and received a $100 million milestone payment from AbbVie. This milestone highlights progress in potential one-time gene therapies for diabetic retinopathy, aiming to reduce vision loss.

View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.